enose video placeholder

Clarity is a breath away

aeoNose exhaled-breath analysis

Better diagnostics are just a breath away.

The eNose company aims to utilize the aeoNose, a portable breath analyzer, to overcome any obstacle that has thusfar prevented early detection of pathologies such as lung- and colon cancer. Our ultimate goal is to save lives and reduce the need for expensive and invasive tests and treatments.

More about The eNose Company
  • A test only takes 15 minutes
  • Ease of use

Detecting diseases through exhaled breath

Detecting lung cancer using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF VALIDATION PROCESS ON LUNG CANCER DETECTION

In 2022, The eNose Company has finalized a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of lung cancer detection. This clinical study was conducted by Dr Sharina Kort MD, and prospective pulmonologist at Medisch Spectrum Twente, Enschede, the Netherlands. Supervisors were Prof Job van der Palen, clinical epidemiologist at Medisch Spectrum Twente, Enschede, the Netherlands and Prof Michel van de Heuvel, pulmonologist at Radboudumc, Nijmegen, the Netherlands. Additionally, several major hospitals in the Netherlands participated in the study as well as the University hospital in Basel, Switzerland. Study results have been accepted for publication in ‘Chest’, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for lung cancer by the end of 2022.

More on lung cancer detection using the aeoNose

Currently, we are validating the aeoNose in the following hospitals

Publications

Training and validating a portable electronic nose for lung cancer screening

R. Van de Goor
M. van Hooren
A.M. Dingemans
B. Kremer
K. Kross

Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis

S. Kort
M.M. Tiggeloven
M. Brusse-Keizer
J.W. Gerritsen
J.H. Schouwink
E. Citgez
F.H.C. de Jongh
S. Samii
J. van der Maten,
M. van den Bogart
J. van der Palen

Improving lung cancer diagnosis by combining exhaled-breath data and clinical parameters

S. Kort
M. M. Brusse-Keizer
J.W. Gerritsen
J.H. Schouwink
E. Citgez
F.H.C. de Jongh
J. van der Maten
S. Samii
M. Van den Bogart
J. van der Palen

Detecting colorectal cancer using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF THE VALIDATION PROCESS ON COLORECTAL CANCER DETECTION

Currently, the eNose Company is finishing up a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of colorectal cancer detection. This clinical study is conducted by Ms. Milou van Riswijk, PhD student and prospective gastro-enterologist. Supervisor is Prof Peter Siersema, gastro-enterologist at Radboudumc, Nijmegen, the Netherlands. Several major hospitals in the Netherlands are participating in the study including Erasmus Medical Center, Rotterdam, the Netherlands. Study results are expected to be ready by the end of 2022 / beginning of 2023, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for colorectal cancer by 2023.

More on colorectal cancer detection using the aeoNose

Currently, we are validating the aeoNose in the following hospitals

Publications

Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer

K.E. van Keulen,
M.E. Jansen,
R.W.M. Schrauwen,
J.J. Kolkman en P.D. Siersema

Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: a pilot study

E.G.M. Steenhuis,
I.J.H. Schoenaker,
J.W.B. de Groot,
H.B. Fiebrich,
J.C. de Graaf,
R.M. Brohet,
J.D. van Dijk,
H.L. van Westreenen,
P.D. Siersema en W.H. de Vos tot Nederveen Cappel

Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device

Y. Peters,
R.W.M. Schrauwen,
A.C. Tan, S.K. Bogers,
B. de Jong, P.D. Siersema

COVID-19 detection using the aeoNose

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict lung cancer in humans.

STATUS OF THE VALIDATION PROCESS ON COVID-19 DETECTION

In close collaboration with ten hospitals in the Netherlands, the eNose Company is involved in a multi-center validation study on detecting COVID-19 using the aeoNose. Our goal is to develop a quick and accurate diagnostic test for healthcare workers. In addition we aim to demonstrate potential to apply the aeoNose as part of an early warning system by tracing and identifying future disease outbreaks.

More on COVID-19 detection using the aeoNose

Currently, we are validating the aeoNose in the following hospitals

Publications

Applying the electronic nose for pre‑operative SARS‑CoV‑2 screening

A.G.W.E. Wintjens,
K.F.H. Hintzen,
S.M.E. Engelen,
T. Lubbers,
P.H.M. Savelkoul,
G. Wesseling, J.A.M. van der Palen en N.D. Bouvy

FAQ

All exhaled-breath tests are being processed in a way that preserves anonymity by encryption. Actual classifications are visible in the electronic patient file only, and therefore not accessible by The eNose Company.

Results are stored in the electronic patient file and are only available to the patient and his/her healthcare professional.

Anonymized, numerical records of all screenings are encrypted and successively stored in an international BreathPrint™ database. Newly added breathprints contribute to improved, more accurate and smarter classification algorithms. In this way, this valuable source of information on exhaled-breath analysis of detectable diseases will be available to healthcare professionals around the globe.

Currently, a breath test for general practitioners is not available yet. However, development of such a test for GPs will start soon for a number of specific indications. At the moment, any trials for a self-test have not been planned.

In case the patient shows symptoms, the general practitioner or physician should consider performing the test, pending compatibility between symptoms and approved applications of the aeoNose.

The risk of cross-contamination is negligible. The following measures are in place to ensure this:

  • For each test, a new disposable mouthpiece is used,
  • For each mouthpiece, a so-called HEPA-filter is mounted, which filters out bacteria and viruses, thereby preventing them from entering the aeoNose device.
  • The patient inhales and exhales through the (new, disposable) mouthpiece, not directly through the aeoNose. The AeoNose has been approved by departments for infection prevention in several Dutch hospitals, including in the case of Covid-19.

News

Detecting lung cancer with electronic nose

Is it possible to detect lung cancer by smelling the air that someone exhales? Sharina Kort, lung specialist in training at MST, recently earned a PhD from the University of Twente (TechMed Centre) based on her research into that topic.

Results of study presented at ERS Barcelona

Sharina Kort MD, PhD presented the results of the study ‘Diagnosing non-small cell lung cancer by exhaled breath profiling using an electronic nose: A multicentre validation study’ on the ERS congress 2022 in Barcelona. Using the aeoNose, lung cancer patients could non-invasively be distinguished from non-lung cancer participants in a multinational validation setting. A paper on this study has recently been accepted by ‘Chest’.
Aeonose breath analysis on TB screening South Africa

Aeonose breath analysis on TB screening South Africa

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.
Guts_eNose

Just published in ‘Gut’, results from a pilot study on Barrett’s oesophagus using the Aeonose

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.
eNose apt

Multicenter study Colon rectal cancer and advanced adenomas

Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett’s oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds (VOCs) analysis with an electronic nose device. This electronic nose was able to distinguish between patients with and without BO with good diagnostic accuracy (sensitivity 91% specificity 74%) and seemed to be independent of proton pump inhibitor use, the presence of hiatal hernia, and reflux. This technique may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy.
eNose peru

Aeonose breath analysis on TB screening Peru

The Union World Conference on Lung Health 2019 was held in Hyderabad (India) from October 30 – November 2. Dr. Ruvandhi Nathavitharana (Harvard University) presented results on the Aeonose exhaled-breath TB-study in Lima, suggesting Aeonose may meet WHO triage test criteria to rule out TB (90% sensitivity, 70% specificity) in lower-risk patients admitted with cough or TB risk factors.
international congress 2019

Improving lung cancer screening results

At the ERS Conference in Madrid (September 28 – October 2, 2019), Sharina Kort (MST, Enschede, the Netherlands) presented clinical study results on diagnosing lung cancer using the Aeonose.
Pancreas new diagnostics

Pancreas new diagnostics

Improved diagnostics for pancreatic diseases are badly needed. An electronic nose (AeoNose™) analysing exhaled breath was successfully used to distinguish between pancreas carcinoma, chronic pancreatitis (inflammation of the pancreas), and healthy controls: promising results from a multicenter pilot study in the Netherlands.
Presentations at DDW San Diego

Presentations at DDW San Diego

At the Digestive Disease Week in San Diego, 4 posters were presented discussing ongoing clinical studies with the Aeonose for exhaled-breath analysis: - Colorectal cancer and advanced adenomas - Barrett’s esophagus (presented both by Radboud University (Nijmegen, the Netherlands) and Mayo Clinic (Rochester)) - Fasting state
Aeonose breath analysis on TB screening Indonesia

Aeonose breath analysis on TB screening Indonesia

Morita Saktiawati, PhD-student working in Yogyakarta, conducted a clinical study in using the Aeonose to detect TB in exhaled breath among TB suspects. Her supervisor was Prof Tjip van der Werf from University Medical Center Groningen, the Netherlands.
All news items on aeoNose

Click below to download the aeoNose user manual

White papers are available free of charge, covering use of the aeoNose, data analysis, background technology, and cost effectiveness.

enose pdf icon User manual aeoNose
© The eNose Company